The Elizabeth Holmes Documentaries Aren’t About Fraud. They’re About Belief.

There’s a familiar rhythm to watching a documentary about Elizabeth Holmes. The opening shots of sunlit Palo Alto offices, the carefully curated voiceover, the mounting sense of dread as investors pour millions into a blood-testing device that never worked. By now, most of us know the ending. Yet we keep watching. Not because we’re searching for new plot twists, but because the story has outgrown Holmes herself. These films have become something quieter and more unsettling: a mirror held up to an entire industry that confused performance with progress.
Early media coverage treated Theranos as an anomaly, a singular bad actor operating inside an otherwise pristine ecosystem. The documentaries, however, gradually strip away that comforting idea. What they reveal is a system that actively rewarded the very traits that made the deception possible. Silicon Valley has long operated on a simple equation: vision justifies the mess. Pitch decks matter more than peer review. Disruption is treated as a virtue, even when it breaks things that shouldn’t be broken. The cameras don’t just follow Holmes; they follow the venture capitalists who ignored red flags, the journalists who were seduced by exclusive access, and the regulatory bodies that arrived only after the collapse. The fraud wasn’t a glitch in the system. It was a predictable outcome of an ecosystem that had forgotten how to verify.
There’s another thread running through these documentaries, one that’s harder to pin down but impossible to ignore. Holmes succeeded not despite her presentation of herself, but because of it. The lowered voice, the tailored turtlenecks, the practiced stillness—these weren’t just personal quirks. They were deliberate costume design for a role that had already been written by decades of male tech founders. The documentaries capture the quiet irony: a woman with a background in chemical engineering was rewarded for performing the part of the enigmatic genius, while actual scientists inside Theranos were sidelined, isolated, or pushed out. The films don’t always spell this out in so many words, but the subtext is clear. The industry didn’t just believe Holmes. It recognized a familiar archetype and handed her the keys.
It’s worth examining what the documentary format does well, and where it inevitably stumbles. Long-form documentary relies on access, interviews, and archival material. In Holmes’s case, that meant piecing together a story from people who had been lied to, fired, or legally bound by silence. The strongest moments in these films let the silence do the heavy lifting. A paused interview. A hesitant answer. The weight of a former employee looking away from the camera. That’s where the truth lives. But documentaries also have a tendency to compress complex timelines into clean arcs. The internal purges, the regulatory negotiations, the financial engineering—they get streamlined into three-act structure. The result is compelling television, but it sometimes flattens the bureaucratic and capital machinery that kept Theranos on life support long after the science had failed.
We keep returning to Elizabeth Holmes not because she’s uniquely fascinating, but because she’s uniquely illuminating. The documentaries about her are less about a single failed company than about the conditions that allowed it to thrive. They ask us to consider what happens when ambition outpaces accountability, when storytelling replaces substance, and when we mistake confidence for competence. The cameras will eventually move on to the next scandal, the next founder, the next breakthrough that turns out to be a mirage. But the questions these films leave behind are still ours to answer. Who gets to sell us a vision? And why are we so eager to buy it?